Sustained drug release by contact lenses for glaucoma treatment—A review

Carvalho, Isabel; Marques, Cláudia; Oliveira, Rita; Barata, Pedro; Costa, Paula Cristina Pereira da; Ferreira, Domingos

doi:10.1016/j.jconrel.2015.01.023

Cited by 128 publications

(87 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consistent with their potential, a surge of recent publications has touted their utility and promise for treating glaucoma through the continuous, long-term release of desired compounds. 128,129 Other researchers have published encouraging reports of sustained control of IOP for a 4-week period with single subconjunctival injections of brimonidine-loaded microspheres. 130 Coated nanoparticles have also been used to deliver medications directly to the intraocular milieu, an approach analogous to the administration of vascular endothelial growth factor inhibitors for the treatment of age-related macular degeneration in humans.…”

Section: Emerging Drug-delivery Platformsmentioning

confidence: 99%

Medical Treatment of Primary Canine Glaucoma

Alario¹,

Strong

Pizzirani

2015

Veterinary Clinics of North America: Small Animal Practice

View full text Add to dashboard Cite

Section: Emerging Drug-delivery Platformsmentioning

confidence: 99%

Medical Treatment of Primary Canine Glaucoma

Alario¹,

Strong

Pizzirani

2015

Veterinary Clinics of North America: Small Animal Practice

View full text Add to dashboard Cite

“…For example, it has 73 been shown that less than 5% of the administered dose reaches 74 the target tissue due to drainage and limited corneal permeability 75 [9 -11]. Moreover, only the anterior segment of the eye can be trea- 76 ted by eye drop installation, whereas different application routes 77 (e.g., intravitreal injections) and/or more complex drug delivery 78 systems (e.g., intraocular implants) may be required to reach the 79 posterior segment [12][13][14][15]. For example, the development of 80 anti-vascular endothelial growth factor (VEGF) drugs, such as mon- 81 oclonal antibodies or antibody fragments, revolutionized the ther- 82 apy of neovascular AMD and other vision-threatening diseases 83 [16][17][18].…”

mentioning

confidence: 99%

Hydrogels in ophthalmic applications

Kirchhof

Goepferich

Brandl

2015

European Journal of Pharmaceutics and Biopharmaceutics

193

View full text Add to dashboard Cite

“…Therefore, many kinds of IOP lowering medications are used to manage the disease symptoms, such as timolol, betaxolol, epinephrine, pilocarpine, and dorzolamide. 3 However, effective treatments are often limited owing to poor bioavailability of topically administered ocular drugs caused by a number of factors, including rapid tear turnover, transient residence time in the cul-de-sac, and washout of tear. 4,5 These factors lead to rapid elimination of the drugs from the precorneal area.…”

Section: Introductionmentioning

confidence: 99%

Controlled drug delivery for glaucoma therapy using montmorillonite/Eudragit microspheres as an ion-exchange carrier

Tian

et al. 2018

IJN

View full text Add to dashboard Cite

Background Glaucoma is a serious eye disease that can lead to loss of vision. Unfortunately, effective treatments are limited by poor bioavailability of antiglaucoma medicine due to short residence time on the preocular surface. Materials and methods To solve this, we successfully prepared novel controlled-release ion-exchange microparticles to deliver betaxolol hydrochloride (BH). Montmorillonite/BH complex (Mt-BH) was prepared by acidification-intercalation, and this complex was encapsulated in microspheres (Mt-BH encapsulated microspheres [BMEMs]) by oil-in-oil emulsion–solvent evaporation method. The BH loaded into ion-exchange Mt was 47.45%±0.54%. After the encapsulation of Mt-BH into Eudragit microspheres, the encapsulation efficiency of BH into Eudragit microspheres was 94.35%±1.01% and BH loaded into Eudragit microspheres was 14.31%±0.47%. Results Both Fourier transform infrared spectra and X-ray diffraction patterns indicated that BH was successfully intercalated into acid-Mt to form Mt-BH and then Mt-BH was encapsulated into Eudragit microspheres to obtain BMEMs. Interestingly, in vitro release duration of the prepared BMEMs was extended to 12 hours, which is longer than both of the BH solution (2.5 hours) and the conventional BH microspheres (5 hours). Moreover, BMEM exhibited lower toxicity than that of BH solution as shown by the results of cytotoxicity tests, chorioallantoic membrane-trypan blue staining, and Draize rabbit eye test. In addition, both in vivo and in vitro preocular retention capacity study of BMEMs showed a prolonged retention time. The pharmacodynamics showed that BMEMs could extend the drug duration of action. Conclusion The developed BMEMs have the potential to be further applied as ocular drug delivery systems for the treatment of glaucoma.

show abstract

Sustained drug release by contact lenses for glaucoma treatment—A review

Cited by 128 publications

References 84 publications

Medical Treatment of Primary Canine Glaucoma

Medical Treatment of Primary Canine Glaucoma

Hydrogels in ophthalmic applications

Controlled drug delivery for glaucoma therapy using montmorillonite/Eudragit microspheres as an ion-exchange carrier

Contact Info

Product

Resources

About